Scout | New Therapeutic Strategies for Genital Herpes (R21/R33 Clinical Trial Not Allowed)

This opportunity is no longer accepting applications.

grant

New Therapeutic Strategies for Genital Herpes (R21/R33 Clinical Trial Not Allowed)

This grant opportunity aims to fund research for new treatments for genital herpes, focusing on suppressing the virus, reducing lesion formation, and minimizing transmission. It invites projects exploring various therapeutic approaches, including new antivirals, monoclonal antibodies, therapeutic vaccines, and gene editing technologies. The funding will be awarded in two phases, with continuat…

Source

Agency: National Institutes of Health

Sub-agency: National Institute of Allergy and Infectious Diseases

Dates

Opportunity Released: October 15, 2024

Open for Submission: October 15, 2024

Submission Deadline: January 31, 2025

Application Window Closes: January 31, 2025

Keywords

genital herpes

antiviral development

therapeutic vaccines

monoclonal antibodies

gene editing

herpes treatment

disease transmission reduction

lesion suppression

milestone-driven funding

clinical research grants

Supporting Links

Documents

Similar Opportunities

Unlock similar opportunities

Get the full picture on this opportunity

Create a free Scout account to unlock everything you need to decide fast and win the grant.

Instant Fit Analysis

Let our grant expert AI score how well this opportunity aligns with your organization, strengths, gaps, and how to improve your chances of winning funding.
Deep agency & funder detail

Program context, sub-agency structure, and a full eligibility breakdown.
Source links & full documents

Jump straight to the solicitation and download every attachment.
Similar opportunities

Discover related funding matched to your work.

Get a Demo Sign Up

Already have an account? Sign In

Trusted by 500+ Happy Customers